Role of SIRT1 in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Chen, I Chieh ^a   Chiang, Wei Fan ^b,c   Huang, Hsin Hsiu ^a   Chen, Pei Fen ^a   Shen, Ying Ying ^a   Chiang, Hung Che ^a,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epithelial to mesenchymal transition; Matrix metalloproteinase 7; Metastasis; Migration; Oral squamous cell carcinoma; Sirtuin 1

Indexed keywords

MATRILYSIN; SIRTUIN 1; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MALE; METASTASIS; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ZYMOGRAPHY; ANIMAL; CELL MOTION; GENETICS; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; MICE; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM METASTASIS; SIRTUIN 1; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84934913426     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-254     Document Type: Article

References (100)

1. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 1, 45:309-316. 10.1016/j.oraloncology.2008.06.002
2. Bsoul SA, Huber MA, Terezhalmy GT: Squamous cell carcinoma of the oral tissues: a comprehensive review for oral healthcare providers. J Contemp Dent Pract 2005, 6:1-16.
3. Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM, Chang KW: Genome-wide profiling of oral squamous cell carcinoma. J Pathol 1, 204:326-332. 10.1002/path.1640
4. Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC: The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med 1, 31:213-219. 10.1034/j.1600-0714.2002.310404.x
5. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ: Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 1, 99:1507-1514. 10.1111/j.1349-7006.2008.00863.x
6. Clayman GL, Lippman SM, Laramore GE, Hong WK: Head and neck cancer. In Cancer Medicine. 4th edition. Edited by: Jolland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. USA: Williams & Wilkins: chapter 105 Philadelphia; 1997:1645-1710.
7. National Cancer Institute: Bethesda: Md: National Cancer Institute; 2009. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: Oral Cavity and Pharynx. 2010. http://seer.cancer.gov/statfacts/html/oralcav.html?statfacts_page=oralcav.html&x . Accessed January 7
8. Ferlito A, Rinaldo A, Devaney KO, MacLennan K, Myers JN, Petruzzelli GJ, Shaha AR, Genden EM, Johnson JT, de Carvalho MB, Myers EN: Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol 1, 38:747-751. 10.1016/S1368-8375(02)00052-0
9. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J: Lymph-Node Prognostic Factors in Head and Neck Squamous-Cell Carcinomas. Am J Surg 1, 168:494-498. 10.1016/S0002-9610(05)80109-6
10. Liao CT, Hsueh C, Lee LY, Lin CY, Fan KH, Wang HM, Huang SF, Chen IH, Kang CJ, Ng SH, Tsao CK, Huang YC, Yen TC: Neck dissection field and lymph node density predict prognosis in patients with oral cavity cancer and pathological node metastases treated with adjuvant therapy. Oral Oncol 1, 48:329-336. 10.1016/j.oraloncology.2011.10.017
11. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 1, 15:740-746. 10.1016/j.ceb.2003.10.006
12. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 1, 7:131-142. 10.1038/nrm1835
13. Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 1, 23:912-923. 10.1002/bies.1132
14. Voulgari A, Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009, 1796:75-90.
15. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN: E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 1994, 7:835-841.
16. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M: Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997, 57:3189-3193.
17. Imamichi Y, Menke A: Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial-mesenchymal transition. Cells Tissues Organs 1, 185:180-190. 10.1159/000101319
18. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH: The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 2009, 284:1385-1393.
19. Shirakihara T, Saitoh M, Miyazono K: Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell 1, 18:3533-3544. 10.1091/mbc.E07-03-0249
20. Deckers M, van Dinther M, Buijs J, Que N, Lowik C, van der Pluijm G, ten Dijke P: The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 1, 66:2202-2209. 10.1158/0008-5472.CAN-05-3560
21. Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 1, 4:118-132. 10.1038/nrc1276
22. Moustakas A, Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 1, 98:1512-1520. 10.1111/j.1349-7006.2007.00550.x
23. Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 1, 403:795-800. 10.1038/35001622
24. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG: Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 1, 65:4000-4018. 10.1007/s00018-008-8357-y
25. Finkel T, Deng CX, Mostoslavsky R: Recent progress in the biology and physiology of sirtuins. Nature 1, 460:587-591. 10.1038/nature08197
26. Lin SJ, Guarente L: Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol 1, 15:241-246. 10.1016/S0955-0674(03)00006-1
27. Donmez G, Guarente L: Aging and disease: connections to sirtuins. Aging Cell 1, 9:285-290. 10.1111/j.1474-9726.2010.00548.x
28. Saunders LR, Verdin E: Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 1, 26:5489-5504. 10.1038/sj.onc.1210616
29. Haigis MC, Guarente LP: Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 1, 20:2913-2921. 10.1101/gad.1467506
30. Michan S, Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J 1, 404:1-13. 10.1042/BJ20070140
31. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I: Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 1, 16:4623-4635. 10.1091/mbc.E05-01-0033
32. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 1, 107:137-148. 10.1016/S0092-8674(01)00524-4
33. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 1, 303:2011-2015. 10.1126/science.1094637
34. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 1, 305:390-392. 10.1126/science.1099196
35. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer (vol 67, pg 6612, 2007). Cancer Res 2007, 67:8423-8423.
36. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y: Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 1, 43:571-579. 10.1016/j.yjmcc.2007.08.008
37. Stunkel W, Peh BK, Tan YC, Nayagam VM, Wang X, Salto-Tellez M, Ni B, Entzeroth M, Wood J: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 1, 2:1360-1368. 10.1002/biot.200700087
38. Sun Y, Sun D, Li F, Tian L, Li C, Li L, Lin R, Wang S: Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 1, 58:21-29. 10.1016/j.lungcan.2007.05.013
39. Hida Y, Kubo Y, Murao K, Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007, 299:103-106. 10.1007/s00403-006-0725-6
40. Potente M, Dimmeler S: Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 1, 7:2117-2122. 10.4161/cc.7.14.6267
41. Liu T, Liu PY, Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 1, 69:1702-1705. 10.1158/0008-5472.CAN-08-3365
42. Dai Y, Faller DV: Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics 2008, 3:53-65.
43. Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K: Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1, 21:627-638. 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.0.CO;2-2
44. de Vicente JC, Lequerica-Fernandez P, Santamaria J, Fresno MF: Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 1, 36:415-424. 10.1111/j.1600-0714.2007.00546.x
45. Li TJ, Cui J: COX-1, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Med 2013, 6:640-643. 10.1016/S1995-7645(13)60110-8
46. Shiomi T, Okada Y: MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 1, 22:145-152. 10.1023/A:1023039230052
47. Kitamura T, Biyajima K, Aoki M, Oshima M, Taketo MM: Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas. Lab Invest 1, 89:98-105. 10.1038/labinvest.2008.107
48. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, Koya D: SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 1, 282:151-158. 10.1074/jbc.M605904200
49. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001, 114:111-118.
50. Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, Min D, Succar L, Rangan GK, Hu M, Henderson BR, Alexander SI, Harris DC: Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 1, 175:580-591. 10.2353/ajpath.2009.080983
51. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 1, 325:834-840. 10.1126/science.1175371
52. Smith J: Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol 1, 12:404-406. 10.1016/S0962-8924(02)02342-5
53. Bordone L, Guarente L: Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 1, 6:298-305. 10.1038/nrm1616
54. Giannakou ME, Partridge L: The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 1, 14:408-412. 10.1016/j.tcb.2004.07.006
55. Guarente L: Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 1, 72:483-488. 10.1101/sqb.2007.72.024
56. Yamamoto H, Schoonjans K, Auwerx J: Sirtuin functions in health and disease. Mol Endocrinol 1, 21:1745-1755. 10.1210/me.2007-0079
57. Baum B, Settleman J, Quinlan MP: Transitions between epithelial and mesenchymal states in development and disease. Seminars Cell Dev Biol 1, 19:294-308. 10.1016/j.semcdb.2008.02.001
58. Kudo Y, Kitajima S, Ogawa I, Hiraoka M, Sargolzaei S, Keikhaee MR, Sato S, Miyauchi M, Takata T: Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 1, 10:5455-5463. 10.1158/1078-0432.CCR-04-0372
59. Kaur G, Carnelio S, Rao N, Rao L: Expression of E-cadherin in primary oral squamous cell carcinoma and metastatic lymph nodes: an immunohistochemical study. Indian J Dent Res 1, 20:71-76. 10.4103/0970-9290.49075
60. Mattijssen V, Pieter H, De Mulder M, Herman MP, Lia S, Bep Van't H-G, Ruiter DJ, Manni JJ: E-cadherin expression in head and neck squamous cell carcinomas associated with clinical outcome. Int J Cancer 1, 55:580-585. 10.1002/ijc.2910550411
61. Bagutti C, Speight PM, Watt FM: Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol 1, 186:8-16. 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H
62. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y: SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 1, 31:4619-4629. 10.1038/onc.2011.612
63. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R: Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 1, 21:266-281. 10.1016/j.ccr.2011.12.020
64. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SHL, Watkins DN, Herman JG, Baylin SB: Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. Plos Genetics 2006, 2:344-352.
65. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q: miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 1, 286:25992-26002. 10.1074/jbc.M111.229401
66. Tryndyak VP, Beland FA, Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010, 126:2575-2583.
67. Kwon HS, Ott M: The ups and downs of SIRT1. Trends Biochem Sci 1, 33:517-525. 10.1016/j.tibs.2008.08.001
68. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY: Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma. Clin Cancer Res 1, 15:4453-4459. 10.1158/1078-0432.CCR-08-3329
69. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, Kang MJ, Lee DG, Kin HS, Shim H, Moon WS: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 1, 32:1523-1531. 10.1097/PAS.0b013e31816b6478
70. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY: Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Human Pathol 1, 42:204-213. 10.1016/j.humpath.2010.05.023
71. Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC: Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009, 11:763-770.
72. Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I, Tobe K: SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 2012, 27:1726-1732.
73. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 1, 3:e2020. 10.1371/journal.pone.0002020
74. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng Z, Appella E, Wang XW, Ried T, Deng CX: Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 1, 14:312-323. 10.1016/j.ccr.2008.09.001
75. Vaziri H, Dessain SK, Eagon EN, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 1, 107:149-159. 10.1016/S0092-8674(01)00527-X
76. Sun L, Li H, Chen J, Dehennaut V, Zhao Y, Yang Y, Iwasaki Y, Kahn-Perles B, Leprince D, Chen Q, Shen A, Xu Y: A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst 1, 105:887-898. 10.1093/jnci/djt118
77. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ: Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 1, 177:1065-1071. 10.2353/ajpath.2010.090923
78. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L: SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 1, 3:1175-1186. 10.1016/j.celrep.2013.03.019
79. Liu P, Wilson MJ: miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-kappaB factor in human fibrosarcoma cells. J Cell Physiol 2012, 227:867-876. 10.1002/jcp.22993
80. Zhang Y, Wang C, Mizukami H, Itoh H, Kusama M, Ozawa K, Jinbu Y: Increased expression and activation of matrix metalloproteinase-2 (MMP-2) in O-1 N: hamster oral squamous cell carcinoma with high potential lymph node metastasis. J Exp Clin Cancer Res 2006, 25:417-423.
81. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 1, 29:564-572. 10.1002/hed.20561
82. Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E: High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 2007, 27:2493-2498.
83. Makinen LK, Hayry V, Hagstrom J, Sorsa T, Passador-Santos F, Keski-Santti H, Haukka J, Makitie AA, Haglund C, Atula T: Matrix metalloproteinase-7 and matrix metalloproteinase-25 in oral tongue squamous cell carcinoma. Head Neck 1, 36:1783-1788. 10.1002/hed.23539
84. Kitamoto K, Machida Y, Uchida J, Izumi Y, Shiota M, Nakao T, Iwao H, Yukimura T, Nakatani T, Miura K: Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci 1, 111:285-292. 10.1254/jphs.09227FP
85. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A: TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 1, 16:1987-2002. 10.1091/mbc.E04-08-0658
86. Takano S, Kanai F, Jazag A, Ijichi H, Yao J, Ogawa H, Enomoto N, Omata M, Nakao A: Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. J Biochem 2007, 141:345-351.
87. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A: Transforming growth factor-beta 1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 1, 282:22089-22101. 10.1074/jbc.M700998200
88. Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 1, 19:156-172. 10.1038/cr.2009.5
89. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 1, 7:415-428. 10.1038/nrc2131
90. Moustakas A, Heldin CH: Induction of epithelial-mesenchymal transition by transforming growth factor beta. Semin Cancer Biol 1, 22:446-454. 10.1016/j.semcancer.2012.04.002
91. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL, Crystal RG, de Herreros AG, Moustakas A, Pettersson RF, Fuxe J: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 1, 11:943-950. 10.1038/ncb1905
92. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 1, 119:1420-1428. 10.1172/JCI39104
93. Yilmaz M, Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 1, 28:15-33. 10.1007/s10555-008-9169-0
94. Nieto MA: The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 1, 27:347-376. 10.1146/annurev-cellbio-092910-154036
95. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 1, 68:3645-3654. 10.1158/0008-5472.CAN-07-2938
96. Yang CC, Tu SF, Chang RC, Kao SY: In vitro cellular response of retinoic acid treated human oral cancer cell lines. Zhonghua Yi Xue Za Zhi (Taipei) 2001, 64:357-363.
97. Lin SC, Liu CJ, Chiu CP, Chang SM, Lu SY, Chen YJ: Establishment of OC3 oral carcinoma cell line and identification of NF-kappa B activation responses to areca nut extract. J Oral Pathol Med 1, 33:79-86. 10.1111/j.1600-0714.2004.00034.x
98. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P: Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 1, 202:265-273. 10.1002/path.1515
99. Yamamoto A, Kasamatsu A, Ishige S, Koike K, Saito K, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H, Uzawa K: Exocyst complex component Sec8: a presumed component in the progression of human oral squamous-cell carcinoma by secretion of matrix metalloproteinases. J Cancer Res Clin Oncol 1, 139:533-542. 10.1007/s00432-012-1356-2
100. Ho BY, Wu YM, Chang KJ, Pan TM: Dimerumic acid inhibits SW620 cell invasion by attenuating H(2)O(2)-mediated MMP-7 expression via JNK/C-Jun and ERK/C-Fos activation in an AP-1-dependent manner. Int J Biol Sci 2011, 7:869-880.